The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies, MRCP, PhD, University of Southampton, Southampton, UK, discusses results from a long-term follow-up of the Phase III REMoDL-B trial (NCT01324596), which investigated whether there was any benefit to adding bortezomib to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with diffuse large B-cell lymphoma (DLBCL). At a median follow-up of five years, improved progression-free and overall survival (PFS; OS) were observed in patients with activated B-Cell (ABC) lymphoma, suggesting that the addition of bortezomib may benefit patients with specific molecular subtypes of DLBCL. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
